avapro and Sepsis
avapro has been researched along with Sepsis in 2 studies
Irbesartan: A spiro compound, biphenyl and tetrazole derivative that acts as an angiotensin II type 1 receptor antagonist. It is used in the management of HYPERTENSION, and in the treatment of kidney disease.
irbesartan : A biphenylyltetrazole that is an angiotensin II receptor antagonist used mainly for the treatment of hypertension.
Sepsis: Systemic inflammatory response syndrome with a proven or suspected infectious etiology. When sepsis is associated with organ dysfunction distant from the site of infection, it is called severe sepsis. When sepsis is accompanied by HYPOTENSION despite adequate fluid infusion, it is called SEPTIC SHOCK.
Research Excerpts
Excerpt | Relevance | Reference |
---|---|---|
"Sepsis is a systemic inflammatory response usually correlated with multi-organ failure." | 1.48 | Cardioprotective effects of irbesartan in polymicrobial sepsis : The role of the p38MAPK/NF-κB signaling pathway. ( Al-Amran, F; Hadi, NR; Yousif, NG; Zigam, QA, 2018) |
Research
Studies (2)
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (50.00) | 24.3611 |
2020's | 1 (50.00) | 2.80 |
Authors
Authors | Studies |
---|---|
Tepebaşi, MY | 1 |
Aşci, H | 1 |
Coşan, S | 1 |
Sevük, MA | 1 |
Karakuyu, NF | 1 |
Özmen, Ö | 1 |
Yousif, NG | 1 |
Hadi, NR | 1 |
Al-Amran, F | 1 |
Zigam, QA | 1 |
Other Studies
2 other studies available for avapro and Sepsis
Article | Year |
---|---|
Irbesartan has a curative effect on lipopolysaccharide-induced cardiotoxicity by antioxidant and antiapoptotic pathways.
Topics: Animals; Antioxidants; Apoptosis; Biomarkers; Cardiotoxicity; Irbesartan; Lipopolysaccharides; Oxida | 2023 |
Cardioprotective effects of irbesartan in polymicrobial sepsis : The role of the p38MAPK/NF-κB signaling pathway.
Topics: Animals; Cardiotonic Agents; Coinfection; Cytokines; Disease Models, Animal; Enzyme Activation; Hemo | 2018 |